SCHEMBL6480157

SCHEMBL6480157

N#Cc1c(NC(=O)c2cccs2)nc2ccccc2c1NCc1ccco1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
NPSR1 Q6W5P4 3/20 0.53
PKM P14618 1/20 0.53
ALDH1A1 P00352 6/20 0.48
HPGD P15428 4/20 0.48
HTT P42858 3/20 0.48
TSHR P16473 2/20 0.48
HSD17B10 Q99714 2/20 0.48
GBA1 P04062 1/20 0.48
KDM4E B2RXH2 7/20 0.46
GAA P10253 3/20 0.46
GLA P06280 1/20 0.46
THRB P10828 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
MAPT P10636 3/20 0.45
ADORA1 P30542 1/20 0.44
LMNA P02545 1/20 0.43
KISS1R Q969F8 4/20 0.42
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480432 0.87 KISS1R (0.49) KMT2AMEN1NPSR1ALDH1A1HTT
SCHEMBL6478801 0.86 ADORA3 (0.49) KMT2AMEN1NPSR1ALDH1A1HPGD
SCHEMBL6487837 0.85 ADORA3 (0.47) KMT2AMEN1NPSR1ALDH1A1HPGD
SCHEMBL5224669 0.81 MEN1 (0.49) KMT2AMEN1NPSR1ALDH1A1HPGD
SCHEMBL6481655 0.77 MEN1 (0.45) KMT2AMEN1NPSR1PKMALDH1A1
SCHEMBL6480107 0.76 ADORA3 (0.46) KMT2AMEN1ALDH1A1HPGDTSHR
Ammonia Solution, Strong SCHEMBL27531632 0.74 KISS1R (0.49) KMT2AMEN1NPSR1ALDH1A1HPGD
SCHEMBL3520995 0.74 KMT2A (0.54) KMT2AMEN1NPSR1ALDH1A1HPGD
SCHEMBL5224949 0.74 ADORA3 (0.48) KMT2AMEN1NPSR1PKMHPGD
SCHEMBL6487647 0.72 MEN1 (0.54) KMT2AMEN1PKMALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390349-B1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SA (FR) 2012-07-25 EP claimed
US-6969723-B2 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI - AVENTIS (FR) 2005-11-29 US claimed
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI (FR) 2004-09-23 US claimed
EP-1390349-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS Sanofi-Aventis (FR) 2004-02-25 EP claimed
WO-2002096879-A9 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SYNTHELABO (FR) 2003-11-20 WO claimed
WO-2002096879-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-SYNTHELABO (FR) 2002-12-05 WO claimed
US-20050119343-A1 Dihydroxy open-acid salt of simvastatin TILLYER RICHARD D (US) 2005-06-02 US disclosed
EP-1324972-A4 DIHYDROXY OPEN-ACID SALT OF SIMVASTATIN MERCK & CO INC (US) 2004-06-30 EP disclosed
US-20030211151-A1 Dihydroxy open-acid and salts of HMG-Co-A reductase inhibitors MERCK & CO., INC. 2003-11-13 US disclosed
US-20030176501-A1 Dihydroxy open-acid salt of simvastatin TILLYER RICHARD D (US) 2003-09-18 US disclosed
EP-1324972-A1 DIHYDROXY OPEN-ACID SALT OF SIMVASTATIN Merck & Co., Inc. (US) 2003-07-09 EP disclosed
US-6569461-B1 Dihydroxy open acid forms of lovastatin, simvastatin, pravastatin and atorvastatin; enteric coated dosage form; substantial release after oral administration is delayed until after passage through the stomach MERCK & CO., INC. 2003-05-27 US disclosed
EP-1036783-B1 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt MERCK & CO INC (US) 2003-05-21 EP disclosed
WO-2002020457-A1 DIHYDROXY OPEN-ACID SALT OF SIMVASTATIN MERCK & CO., INC. (US) 2002-03-14 WO disclosed
EP-1163203-A1 CRYSTALLINE HYDRATED DIHYDROXY OPEN-ACID SIMVASTATIN CALCIUM SALT Merck & Co., Inc. (US) 2001-12-19 EP disclosed
EP-1161236-A1 DIHYDROXY OPEN-ACID AND SALTS OF HMG-CO-A REDUCTASE INHIBITORS Merck & Co., Inc. (US) 2001-12-12 EP disclosed
EP-1036783-A1 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt MERCK & CO. INC. (US) 2000-09-20 EP disclosed
EP-1036563-A1 Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof MERCK & CO. INC. (US) 2000-09-20 EP disclosed
WO-2000053566-A1 CRYSTALLINE HYDRATED DIHYDROXY OPEN-ACID SIMVASTATIN CALCIUM SALT MERCK & CO., INC. (US) 2000-09-14 WO disclosed
WO-2000053173-A1 DIHYDROXY OPEN-ACID AND SALTS OF HMG-CO-A REDUCTASE INHIBITORS MERCK & CO., INC. (US) 2000-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119343-A1 Dihydroxy open-acid salt of simvastatin HMGCR, DHCR7, CYP46A1 KMT2A 2677/4885MEN1 997/4885NPSR1 1379/4885
US-20030211151-A1 Dihydroxy open-acid and salts of HMG-Co-A reductase inhibitors HMGCR, CYP46A1, DHCR7 KMT2A 1743/4885MEN1 2104/4885NPSR1 745/4885
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands ADORA3, ADORA1, ADORA2A KMT2A 2739/4885MEN1 3078/4885NPSR1 568/4885
US-20030176501-A1 Dihydroxy open-acid salt of simvastatin HMGCR, DHCR7, CYP46A1 KMT2A 2677/4885MEN1 997/4885NPSR1 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.